Overview

No study in the sources checked tests BPC-157 and GHK-Cu together. This page therefore sets out what each peptide has been studied for separately and does not claim a combined effect.

BPC-157

In the chick chorioallantoic membrane and endothelial tube formation assays, BPC 157 increased vessel density. It sped blood flow recovery in rat ischemic hind limb and increased VEGFR2 expression, internalization and activation of the VEGFR2-Akt-eNOS pathway in human endothelial cells (Hsieh 2017). A systematic review of the orthopaedic literature found 36 studies (35 preclinical, 1 clinical) and noted BPC-157 lacks US FDA approval (Vasireddi 2025).

GHK-Cu

Reviews describe stimulation of collagen, decorin and other matrix components and modulation of metalloproteinases (Pickart 2015). In 72 rats after ACL reconstruction, intra-articular GHK-Cu improved knee laxity at 6 weeks but not at 12 weeks (Fu 2015).

FindingModelSource
VEGFR2 expression, internalization and Akt-eNOS activation; more vesselsEndothelial cells, CAM assay, rat hind limbHsieh 2017
36 studies in the literature: 35 preclinical, 1 clinicalSystematic reviewVasireddi 2025
Stimulates collagen, decorin and metalloproteinase modulationReviewPickart 2015
Lower knee laxity at 6 weeks, not at 12 weeks72 rats after ACL reconstructionFu 2015

What the sources do not show

  • No source checked tests the two together, so no complementary effect is claimed.
  • Claims that they do not interfere with each other were not tested in the sources checked.
  • Specific BPC-157 pathway claims (FAK-paxillin, ERK1/2, tendon fibroblast and hepatocyte cytoprotection) are not covered by the sources checked.
  • The Hsieh study used BPC 157 in endothelial and animal assays, not in tendon or collagen assays.

Related research products and tools

Frequently Asked Questions

Has BPC-157 been tested with GHK-Cu?

Not in the sources checked.

What does BPC-157 do in angiogenesis assays?

It increased vessel density and activated VEGFR2-Akt-eNOS signalling (Hsieh 2017).

Is BPC-157 approved?

The 2025 systematic review notes it lacks US FDA approval (Vasireddi 2025).

Key References

  • Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017. PubMed 27847966
  • Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed 40756949
  • Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PubMed 26236730
  • Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PubMed 25731775

For research use only. Not for human consumption.